Patient Support Program

Select Language

The VEOZAH^® CONNECT PSP has been designed to help facilitate the treatment journey with VEOZAH for you and your patients, offering a wide array of benefits, including an enrolment support, financial support, a call centre available 8 am-8 pm EST, adherence support, and ongoing patient updates and reminders.

Enrolment support

Welcome call

Financial assistance and bridging support

Reimbursement navigation

Adherence support and adverse event (AE) monitoring

Live telephone support

Ongoing patient updates and reminders

Enrol your patients today to help facilitate their treatment
 journey with VEOZAH!

A woman and a man walks hand in hand near by the beach

For more information on VEOZAH or how to enrol your patients in the VEOZAH^® CONNECT Patient Support Program, reach out to your VEOZAH representative or call the PSP directly.

Phone: 1-844-583-6924 (1-844-5VEOZAH)
Fax: 1-877-298-5167
Email: support@veozahconnect.ca

Important Safety Information

Read less

Indication body title

Clinical use:

Pediatrics (<18 years of age): not indicated.
Geriatrics (≥65 years of age): no data available; therefore, an indication has not been recommended.

Contraindications:

Known cirrhosis
Severe renal impairment or end-stage renal disease
Patients using concomitant moderate or strong CYP1A2 inhibitors
Known or suspected pregnancy

Relevant warnings and precautions:

Benefit-risk consideration to treat women with known or previous breast cancer or other estrogen-dependent malignancies
Not recommended in Child-Pugh Class B (moderate) chronic hepatic impairment; not studied in Child-Pugh Class C (severe) chronic hepatic impairment and is not recommended in this population
Risk of hepatic transaminase elevation and hepatotoxicity
Perform baseline bloodwork to evaluate hepatic function and assess for injury (including serum ALT, serum AST, serum ALP, and serum bilirubin [total and direct]) prior to initiating VEOZAH. Perform hepatic laboratory tests monthly for the first 3 months, at 6 months, and 9 months after initiation of therapy
Incidence of other malignancies; a causal relationship between VEOZAH and increased risk of malignancies has not been established
Risk of endometrial hyperplasia and endometrial carcinoma. In the VEOZAH 45 mg dose group across the three phase 3 studies, endometrial biopsy assessments identified one case of endometrial hyperplasia and one case of endometrial malignancy (0.6% with a one-sided upper limit of 95% confidence of 1.8%). The rate of these events in the VEOZAH 45 mg dose group was ≤1% with the upper bound of the one-sided 95% confidence limit being ≤4%. There was no case of endometrial hyperplasia or carcinoma in the placebo group
Not recommended in breast-feeding women

For more information:

Consult the Product Monograph at www.veozahmonograph.ca for important information relating to adverse reactions, drug interactions and dosing information. The Product Monograph is also available by calling 1-888-338-1824.

Important Safety Information

Read less

Indication body title

Clinical use:

Pediatrics (<18 years of age): not indicated.
Geriatrics (≥65 years of age): no data available; therefore, an indication has not been recommended.

Contraindications:

Known cirrhosis
Severe renal impairment or end-stage renal disease
Patients using concomitant moderate or strong CYP1A2 inhibitors
Known or suspected pregnancy

Relevant warnings and precautions:

Benefit-risk consideration to treat women with known or previous breast cancer or other estrogen-dependent malignancies
Not recommended in Child-Pugh Class B (moderate) chronic hepatic impairment; not studied in Child-Pugh Class C (severe) chronic hepatic impairment and is not recommended in this population
Risk of hepatic transaminase elevation and hepatotoxicity
Perform baseline bloodwork to evaluate hepatic function and assess for injury (including serum ALT, serum AST, serum ALP, and serum bilirubin [total and direct]) prior to initiating VEOZAH. Perform hepatic laboratory tests monthly for the first 3 months, at 6 months, and 9 months after initiation of therapy
Incidence of other malignancies; a causal relationship between VEOZAH and increased risk of malignancies has not been established
Risk of endometrial hyperplasia and endometrial carcinoma. In the VEOZAH 45 mg dose group across the three phase 3 studies, endometrial biopsy assessments identified one case of endometrial hyperplasia and one case of endometrial malignancy (0.6% with a one-sided upper limit of 95% confidence of 1.8%). The rate of these events in the VEOZAH 45 mg dose group was ≤1% with the upper bound of the one-sided 95% confidence limit being ≤4%. There was no case of endometrial hyperplasia or carcinoma in the placebo group
Not recommended in breast-feeding women

For more information:

Jump to top

*Comparative clinical significance unknown.

^†SKYLIGHT 2 was a Phase 3, randomized, double-blind, placebo-controlled, parallel-group, study in which post-menopausal women were randomized to VEOZAH 45 mg (n=167) or placebo (n=167) once daily for 12 weeks. After the 12-week, double-blind treatment period, all patients received VEOZAH for a 40-week extension treatment period with women on placebo re-randomized to VEOZAH to evaluate safety for up to 52 weeks total exposure. The study included post-menopausal women who had a minimum average of 7 moderate to severe VMS per day. The coprimary efficacy endpoints were change from baseline in moderate to severe VMS frequency and severity to weeks 4 and 12. Baseline mean frequency of moderate to severe VMS per 24 hours: 11.8 for VEOZAH, 11.6 for placebo.¹

^‡Clinical significance is unknown.

Select Language

Enrol your patients today to help facilitate their treatment journey with VEOZAH!

For more information on VEOZAH or how to enrol your patients in the VEOZAH® CONNECT Patient Support Program, reach out to your VEOZAH representative or call the PSP directly.

Enrol your patients today to help facilitate their treatment
 journey with VEOZAH!

For more information on VEOZAH or how to enrol your patients in the VEOZAH^® CONNECT Patient Support Program, reach out to your VEOZAH representative or call the PSP directly.